Industry leader in exoskeleton technology for medical and industrial use Ekso Bionics Holdings, Inc., which is headquartered in California, US, has announced the publication of data from a multi-centre pan-European study that assessed the company’s wearable exoskeleton, EksoGT, in a ‘diverse and representative spinal cord injury (SCI) population’.
The results – which were published in the International Spinal Cord Society’s (ISCOS) peer-reviewed journal, Spinal Cord – showed that EksoGT is safe and feasible for use and improved training characteristics and changes in gait function for those with SCI. This includes those with paraplegia and tetraplegia, recent and chronic injuries, as well as complete or incomplete SCI.
“The pan-Euro study is one of the first to evaluate wearable exoskeletons in a heterogeneous SCI population, providing additional insights across a wider range of patients. Previous exoskeleton studies focused on complete SCI,” commented Thomas Looby, president and CEO of Ekso Bionics. “In combination with the 35 US studies and 25 EMEA studies conducted with the EksoGT, we are paving the way on quantifying the benefits of exoskeleton gait rehabilitation and ultimately redefining rehabilitation for a broader range of patients with SCI.”